GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology therapies built on its proprietary TriKE® and Dual Targeting TriKE® platforms. Its programs are designed to harness a patient’s natural killer cells to attack cancer, but the company remains pre-commercial and dependent on financing to fund development.

3.50

3.50

— GT Biopharma, Inc.
%
TriKE® platform therapeutics70% Multi-specific biologic drug candidates designed to activate natural killer cells against cancer.
Dual Targeting TriKE® therapeutics20% Next-generation platform programs that target two cancer-related antigens while engaging NK cells.
Research and development services10% Internal discovery, translational work, and clinical development activities supporting the pipeline.

GT Biopharma does not sell a commercial product base today; its primary stakeholders are clinical investigators,...

  • Clinical and research collaboratorsprimary

    Academic and clinical partners that support translational research, trial execution, and data generation for the pipeline.

  • Regulatory authoritiesprimary

    FDA and comparable agencies that review safety, efficacy, manufacturing, and labeling before commercialization.

  • Future oncology treatment providerssecondary

    Hospitals, cancer centers, and oncologists that would prescribe or administer approved therapies.

  • Cancer patientssecondary

    Patients with malignancies that may be eligible for NK-cell engaging immuno-oncology treatments.

The company is headquartered in the United States and operates as a U.S.-based clinical-stage biotech...

  • •Headquartered in the United States
  • •No disclosed country revenue mix in the excerpts
  • •Development work is centered on U.S. regulatory pathways
  • •Future commercialization would likely depend on U.S. and global approvals

GT Biopharma’s strategy is centered on advancing its TriKE® and Dual Targeting TriKE® platforms through development and...

01
Secure additional financingshort-term

The company disclosed substantial doubt about its ability to continue as a going concern without new capital.

02
Advance clinical-stage immune-oncology programsmedium-term

Pipeline progress is the main value driver for a pre-commercial biotech.

03
Maintain and defend intellectual propertymedium-term

Platform protection is critical to differentiation and future partnering or commercialization.

The company faces classic clinical-stage biotech risks: financing dependence, regulatory uncertainty, and the...

critical

Going concern and liquidity shortfall

Management stated existing cash may not fund operations for one year without additional financing.

Scope
Funding of R&D, overhead, and clinical development
Materiality
high
high

Clinical development and regulatory failure

Product candidates may not demonstrate safety or efficacy, and approvals are uncertain.

Scope
Pipeline programs and future commercialization
Materiality
high
high

Competition from larger biotech and pharma companies

Competitors have greater capital, manufacturing, and regulatory resources.

Scope
Market access, patent position, and speed to commercialization
Materiality
high
high

Intellectual property compromise

Loss or weakening of IP protection could reduce exclusivity and partnering value.

Scope
TriKE® platform and related therapeutics
Materiality
high
medium

FDA and post-approval compliance

Even approved products remain subject to manufacturing, labeling, and surveillance requirements.

Scope
Future approved products and clinical operations
Materiality
medium
Going concern
Affects financial statement basis and investor assessment of solvency
Warrant liability fair value
Can create periodic non-cash gains or losses
Deferred offering costs
Affects current assets and equity transaction accounting
Accrued expenses and accounts payable
Can materially affect current liabilities and liquidity presentation

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

Grace Therapeutics, Inc.

GRCE · Pharmaceutical Preparations

Xeris Biopharma Holdings, Inc.

XERS · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Matinas BioPharma Holdings, Inc.

MTNB · Pharmaceutical Preparations

TG THERAPEUTICS, INC.

TGTX · Pharmaceutical Preparations

: 28.4.2026